

Francine BÃ©har-Cohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1711434/publications.pdf>

Version: 2024-02-01

132
papers

5,826
citations

81839

39
h-index

91828

69
g-index

144
all docs

144
docs citations

144
times ranked

5074
citing authors

#	ARTICLE	IF	CITATIONS
1	Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Progress in Retinal and Eye Research, 2015, 48, 82-118.	7.3	712
2	Mechanisms of macular edema: Beyond the surface. Progress in Retinal and Eye Research, 2018, 63, 20-68.	7.3	422
3	Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. Journal of Clinical Investigation, 2012, 122, 2672-2679.	3.9	316
4	MINERALOCORTICOID RECEPTOR ANTAGONISM IN THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2013, 33, 2096-2102.	1.0	188
5	Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2020, 395, 294-303.	6.3	134
6	Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disorders. Progress in Retinal and Eye Research, 2022, 86, 100973.	7.3	133
7	The outer limiting membrane (OLM) revisited: clinical implications. Clinical Ophthalmology, 2010, 4, 183.	0.9	132
8	The neuroretina is a novel mineralocorticoid target: aldosterone upregulates ion and water channels in Müller glial cells. FASEB Journal, 2010, 24, 3405-3415.	0.2	129
9	Light-induced retinal damage using different light sources, protocols and rat strains reveals LED phototoxicity. Neuroscience, 2016, 339, 296-307.	1.1	119
10	SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2015, 35, 2505-2515.	1.0	116
11	ACUTE CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2017, 37, 1905-1915.	1.0	102
12	Sustained release of nanosized complexes of polyethylenimine and anti-TGF- β 2 oligonucleotide improves the outcome of glaucoma surgery. Journal of Controlled Release, 2006, 112, 369-381.	4.8	93
13	Oral Mineralocorticoid-Receptor Antagonists: Real-Life Experience in Clinical Subtypes of Nonresolving Central Serous Chorioretinopathy With Chronic Epitheliopathy. Translational Vision Science and Technology, 2016, 5, 2.	1.1	89
14	Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives. Drug Discovery Today, 2019, 24, 1685-1693.	3.2	78
15	Dexamethasone-loaded poly(ϵ -caprolactone) intravitreal implants: A pilot study. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 68, 637-646.	2.0	76
16	Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye. Investigative Ophthalmology and Visual Science, 2002, 43, 1533-9.	3.3	75
17	Ultraviolet damage to the eye revisited: eye-sun protection factor (E-SPF®), a new ultraviolet protection label for eyewear. Clinical Ophthalmology, 2014, 8, 87.	0.9	73
18	Placental Growth Factor Contributes to Micro-Vascular Abnormalization and Blood-Retinal Barrier Breakdown in Diabetic Retinopathy. PLoS ONE, 2011, 6, e17462.	1.1	65

#	ARTICLE	IF	CITATIONS
19	Multimodal Imaging-Based Central Serous Chorioretinopathy Classification. <i>Ophthalmology Retina</i> , 2020, 4, 1043-1046.	1.2	64
20	Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. <i>Acta Ophthalmologica</i> , 2018, 96, e1-e9.	0.6	60
21	Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNF- α soluble receptor in uveitis. <i>FASEB Journal</i> , 2006, 20, 389-391.	0.2	59
22	RISK FACTORS FOR RECURRENCES OF CENTRAL SEROUS CHORIORETINOPATHY. <i>Retina</i> , 2018, 38, 1403-1414.	1.0	59
23	Pharmacokinetics and Posterior Segment Biodistribution of ESBA105, an Anti- α -TNF Single-Chain Antibody, upon Topical Administration to the Rabbit Eye. , 2009, 50, 771.		58
24	Cone Genesis Tracing by the Chrn4-EGFP Mouse Line: Evidences of Cellular Material Fusion after Cone Precursor Transplantation. <i>Molecular Therapy</i> , 2017, 25, 634-653.	3.7	56
25	Electrically Assisted Ocular Gene Therapy. <i>Survey of Ophthalmology</i> , 2007, 52, 196-208.	1.7	55
26	Ocular gene therapy: a review of nonviral strategies. <i>Molecular Vision</i> , 2006, 12, 1334-47.	1.1	55
27	A New CRB1 Rat Mutation Links Müller Glial Cells to Retinal Telangiectasia. <i>Journal of Neuroscience</i> , 2015, 35, 6093-6106.	1.7	54
28	En Face Optical Coherence Tomography of Foveal Microstructure in Full-Thickness Macular Hole: A Model to Study Perifoveal Müller Cells. <i>American Journal of Ophthalmology</i> , 2015, 159, 1142-1151.e3.	1.7	52
29	Shift Work: A Risk Factor for Central Serous Chorioretinopathy. <i>American Journal of Ophthalmology</i> , 2016, 165, 23-28.	1.7	52
30	Suprachoroidal Electrotransfer: A Nonviral Gene Delivery Method to Transfect the Choroid and the Retina Without Detaching the Retina. <i>Molecular Therapy</i> , 2012, 20, 1559-1570.	3.7	50
31	Blood-brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of P-glycoprotein on a novel verapamil influx carrier. <i>British Journal of Pharmacology</i> , 2016, 173, 497-510.	2.7	50
32	VOLUME-RENDERED ANGIOGRAPHIC AND STRUCTURAL OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF MACULAR TELANGIECTASIA TYPE 2. <i>Retina</i> , 2017, 37, 424-435.	1.0	50
33	Oligonucleotide-Polyethylenimine Complexes Targeting Retinal Cells: Structural Analysis and Application to Anti-TGF β 2 Therapy. <i>Pharmaceutical Research</i> , 2006, 23, 770-781.	1.7	48
34	In vitro and in vivo ocular biocompatibility of electrospun poly(ϵ -caprolactone) nanofibers. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 73, 9-19.	1.9	48
35	Iron is neurotoxic in retinal detachment and transferrin confers neuroprotection. <i>Science Advances</i> , 2019, 5, eaau9940.	4.7	48
36	Downregulation of IRS-1 Expression Causes Inhibition of Corneal Angiogenesis. , 2005, 46, 4072.		47

#	ARTICLE	IF	CITATIONS
37	Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration. <i>Nature Communications</i> , 2019, 10, 369.	5.8	47
38	PKCÎ¶ Mediates Breakdown of Outer Blood-Retinal Barriers in Diabetic Retinopathy. <i>PLoS ONE</i> , 2013, 8, e81600.	1.1	46
39	Comparison of two mineralocorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. <i>International Ophthalmology</i> , 2017, 37, 1115-1125.	0.6	46
40	Discrepancy in current central serous chorioretinopathyÄclassification. <i>British Journal of Ophthalmology</i> , 2019, 103, 737-742.	2.1	45
41	Poly-Îµ-Caprolactone Intravitreal Devices: An In Vivo Study. , 2009, 50, 2312.		43
42	Glucocorticoids induce retinal toxicity through mechanisms mainly associated with paraptosis. <i>Molecular Vision</i> , 2007, 13, 1746-57.	1.1	43
43	PATTERNS OF CHORIOCAPILLARIS FLOW SIGNAL VOIDS IN CENTRAL SEROUS CHORIORETINOPATHY. <i>Retina</i> , 2019, 39, 2178-2188.	1.0	40
44	Cutaneous Wound Healing in Diabetic Mice Is Improved by Topical Mineralocorticoid Receptor Blockade. <i>Journal of Investigative Dermatology</i> , 2020, 140, 223-234.e7.	0.3	40
45	Pachychoroid: current concepts on clinical features and pathogenesis. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2021, 259, 1385-1400.	1.0	40
46	On the retinal toxicity of intraocular glucocorticoids. <i>Biochemical Pharmacology</i> , 2010, 80, 1878-1886.	2.0	38
47	Glucocorticoids Exert Direct Toxicity on Microvasculature: Analysis of Cell Death Mechanisms. <i>Toxicological Sciences</i> , 2015, 143, 441-453.	1.4	36
48	ROCK-1 mediates diabetes-induced retinal pigment epithelial and endothelial cell blebbing: Contribution to diabetic retinopathy. <i>Scientific Reports</i> , 2017, 7, 8834.	1.6	36
49	Ocular biocompatibility of dexamethasone acetate loaded poly(É-caprolactone) nanofibers. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 142, 20-30.	2.0	36
50	Proteome and Metabolome of Subretinal Fluid in Central Serous Chorioretinopathy and Rhegmatogenous Retinal Detachment: A Pilot Case Study. <i>Translational Vision Science and Technology</i> , 2018, 7, 3.	1.1	34
51	Review: The bile acids urso- and tauroursodeoxycholic acid as neuroprotective therapies in retinal disease. <i>Molecular Vision</i> , 2019, 25, 610-624.	1.1	33
52	VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo. <i>Molecular Vision</i> , 2005, 11, 184-91.	1.1	33
53	Resolution of foveal detachment in dome-shaped macula after treatment by spironolactone: report of two cases and mini-review of the literature. <i>Clinical Ophthalmology</i> , 2014, 8, 999.	0.9	32
54	Macular Telangiectasia Type 1: Capillary Density and Microvascular Abnormalities Assessed by Optical Coherence Tomography Angiography. <i>American Journal of Ophthalmology</i> , 2016, 167, 18-30.	1.7	32

#	ARTICLE	IF	CITATIONS
55	From Rust to Quantum Biology: The Role of Iron in Retina Physiopathology. <i>Cells</i> , 2020, 9, 705.	1.8	32
56	Did the COVID-19 Pandemic Increase the Incidence of Acute Macular Neuroretinopathy?. <i>Journal of Clinical Medicine</i> , 2021, 10, 5038.	1.0	32
57	Targeting iron-mediated retinal degeneration by local delivery of transferrin. <i>Free Radical Biology and Medicine</i> , 2015, 89, 1105-1121.	1.3	30
58	The Aldosterone-Mineralocorticoid Receptor Pathway Exerts Anti-Inflammatory Effects in Endotoxin-Induced Uveitis. <i>PLoS ONE</i> , 2012, 7, e49036.	1.1	30
59	High Prevalence of PRPH2 in Autosomal Dominant Retinitis Pigmentosa in France and Characterization of Biochemical and Clinical Features. <i>American Journal of Ophthalmology</i> , 2015, 159, 302-314.	1.7	29
60	Corticosteroids and the retina. <i>Current Opinion in Neurology</i> , 2016, 29, 49-54.	1.8	29
61	Tolerance of high and low amounts of PLGA microspheres loaded with mineralocorticoid receptor antagonist in retinal target site. <i>Journal of Controlled Release</i> , 2017, 266, 187-197.	4.8	29
62	Early Effects of Intravitreal Triamcinolone on Macular Edema. <i>Ophthalmology</i> , 2006, 113, 2048-2053.	2.5	28
63	Ocular biocompatibility of a poly(ortho ester) characterized by autocatalyzed degradation. <i>Journal of Biomedical Materials Research Part B</i> , 2003, 67A, 44-53.	3.0	27
64	Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy. <i>British Journal of Ophthalmology</i> , 2019, 103, 1184-1189.	2.1	26
65	Treatment of Uveitis by In Situ Administration of Ex VivoÄ© Activated Polyclonal Regulatory T Cells. <i>Journal of Immunology</i> , 2016, 196, 2109-2118.	0.4	25
66	Central Serous Chorioretinopathy. <i>Developments in Ophthalmology</i> , 2017, 58, 27-38.	0.1	25
67	Effect of acute and chronic aldosterone exposure on the retinal pigment epithelium-choroid complex in rodents. <i>Experimental Eye Research</i> , 2019, 187, 107747.	1.2	25
68	Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence. <i>Experimental Eye Research</i> , 2019, 187, 107754.	1.2	25
69	Transscleral optical phase imaging of the human retina. <i>Nature Photonics</i> , 2020, 14, 439-445.	15.6	25
70	Choroidal Mast Cells in Retinal Pathology. <i>American Journal of Pathology</i> , 2015, 185, 2083-2095.	1.9	24
71	Non-viral ocular gene therapy, pEYS606, for the treatment of non-infectious uveitis: Preclinical evaluation of the medicinal product. <i>Journal of Controlled Release</i> , 2018, 285, 244-251.	4.8	24
72	Single-stranded oligonucleotide-mediated in vivo gene repair in the rd1 retina. <i>Molecular Vision</i> , 2007, 13, 692-706.	1.1	24

#	ARTICLE	IF	CITATIONS
73	Local Ocular Immunomodulation Resulting from Electrotransfer of Plasmid Encoding Soluble TNF Receptors in the Ciliary Muscle. , 2009, 50, 1761.		23
74	Central serous chorioretinopathy imaging biomarkers. British Journal of Ophthalmology, 2022, 106, 553-558.	2.1	23
75	Effects of triamcinolone acetonide on vessels of the posterior segment of the eye. Molecular Vision, 2009, 15, 2634-48.	1.1	23
76	Overexpressed or intraperitoneally injected human transferrin prevents photoreceptor degeneration in rd10 mice. Molecular Vision, 2010, 16, 2612-25.	1.1	23
77	Evaluation of tolerance to lentiviral LV-RPE65 gene therapy vector after subretinal delivery in non-human primates. Translational Research, 2017, 188, 40-57.e4.	2.2	21
78	The ciliary smooth muscle electrotransfer: basic principles and potential for sustained intraocular production of therapeutic proteins. Journal of Gene Medicine, 2010, 12, 904-919.	1.4	20
79	The protective role of transferrin in Müller glial cells after iron-induced toxicity. Molecular Vision, 2008, 14, 928-41.	1.1	20
80	Enhanced oligonucleotide delivery to mouse retinal cells using iontophoresis. Molecular Vision, 2006, 12, 1098-107.	1.1	20
81	Predictors of treatment response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation secondary to chronic central serous chorioretinopathy. British Journal of Ophthalmology, 2020, 104, 910-916.	2.1	18
82	The antidiabetic drug glibenclamide exerts direct retinal neuroprotection. Translational Research, 2021, 229, 83-99.	2.2	18
83	Fluocinolone acetonide implant in diabetic macular edema: International experts' panel consensus guidelines and treatment algorithm. European Journal of Ophthalmology, 2022, 32, 1890-1899.	0.7	17
84	Ocular Distribution, Spectrum of Activity, and <i>In Vivo</i> Viral Neutralization of a Fully Humanized Anti-Herpes Simplex Virus IgG Fab Fragment following Topical Application. Antimicrobial Agents and Chemotherapy, 2012, 56, 1390-1402.	1.4	16
85	Sustained-Release Steroids for the Treatment of Diabetic Macular Edema. Current Diabetes Reports, 2015, 15, 99.	1.7	16
86	On the use of an appropriate TdT-mediated dUTP-biotin nick end labeling assay to identify apoptotic cells. Analytical Biochemistry, 2015, 480, 37-41.	1.1	15
87	CONCURRENT IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2 AND CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2018, 38, S67-S78.	1.0	15
88	Recent advances in slow and sustained drug release for retina drug delivery. Expert Opinion on Drug Delivery, 2019, 16, 679-686.	2.4	15
89	Validation of central serous chorioretinopathy multimodal imaging-based classification system. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 1161-1169.	1.0	15
90	CHANGES IN VISUAL ACUITY AND PHOTORECEPTOR DENSITY USING ADAPTIVE OPTICS AFTER RETINAL DETACHMENT REPAIR. Retina, 2020, 40, 376-386.	1.0	14

#	ARTICLE	IF	CITATIONS
91	Mineralocorticoid Receptor Pathway and Its Antagonism in a Model of Diabetic Retinopathy. <i>Diabetes</i> , 2021, 70, 2668-2682.	0.3	14
92	EFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE. <i>Retina</i> , 2017, 37, 2226-2237.	1.0	13
93	Oral Ursodeoxycholic Acid Crosses the Blood Retinal Barrier in Patients with Retinal Detachment and Protects Against Retinal Degeneration in an Ex Vivo Model. <i>Neurotherapeutics</i> , 2021, 18, 1325-1338.	2.1	13
94	Ocular Barriers and Their Influence on Gene Therapy Products Delivery. <i>Pharmaceutics</i> , 2022, 14, 998.	2.0	13
95	Long-Term Oral Treatment with Non-Hypoglycemic Dose of Glibenclamide Reduces Diabetic Retinopathy Damage in the Goto-Kakizaki Rat Model. <i>Pharmaceutics</i> , 2021, 13, 1095.	2.0	12
96	Bioactive Glass Nanoparticles-Loaded Poly(ϵ -caprolactone) Nanofiber as Substrate for ARPE-19 Cells. <i>Journal of Nanomaterials</i> , 2016, 2016, 1-12.	1.5	11
97	Transferrin Non-Viral Gene Therapy for Treatment of Retinal Degeneration. <i>Pharmaceutics</i> , 2020, 12, 836.	2.0	11
98	Pathogenic Effects of Mineralocorticoid Pathway Activation in Retinal Pigment Epithelium. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9618.	1.8	11
99	Mid-Phase Hyperfluorescent Plaques Seen on Indocyanine Green Angiography in Patients with Central Serous Chorioretinopathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 4525.	1.0	11
100	Ocular safety of Intravitreal Clindamycin Hydrochloride Released by PLGA Implants. <i>Pharmaceutical Research</i> , 2017, 34, 1083-1092.	1.7	10
101	The Academicâ€œIndustrial Complexity: Failure to Launch. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 1052-1060.	4.0	10
102	Glial cells of the human fovea. <i>Molecular Vision</i> , 2020, 26, 235-245.	1.1	10
103	COVID-19 Associated Choroidopathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 4686.	1.0	9
104	The Use of Polymer Blends in the Treatment of Ocular Diseases. <i>Pharmaceutics</i> , 2022, 14, 1431.	2.0	9
105	Towards an Optimized Use of Ocular Corticosteroids: EURETINA Award Lecture 2017. <i>Ophthalmologica</i> , 2018, 240, 111-119.	1.0	8
106	Choroidal imaging in patients with Cushing syndrome. <i>Acta Ophthalmologica</i> , 2021, 99, 533-537.	0.6	8
107	Chronic Systemic Dexamethasone Regulates the Mineralocorticoid/Glucocorticoid Pathways Balance in Rat Ocular Tissues. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1278.	1.8	8
108	Mineralocorticoid pathway in retinal health and diseases. <i>British Journal of Pharmacology</i> , 2022, 179, 3190-3204.	2.7	8

#	ARTICLE	IF	CITATIONS
109	Drug delivery to the eye: current trends and future perspectives. <i>Therapeutic Delivery</i> , 2012, 3, 1135-1137.	1.2	7
110	Angiotensin II and aldosterone: Co-conspirators in ocular physiology and disease. <i>Experimental Eye Research</i> , 2020, 194, 108005.	1.2	7
111	Management of central serous chorioretinopathy: Expert panel discussion. <i>Indian Journal of Ophthalmology</i> , 2018, 66, 1700.	0.5	7
112	An in vitro Model of Human Retinal Detachment Reveals Successive Death Pathway Activations. <i>Frontiers in Neuroscience</i> , 2020, 14, 571293.	1.4	6
113	Wnt6 plays a complex role in maintaining human limbal stem/progenitor cells. <i>Scientific Reports</i> , 2021, 11, 20948.	1.6	6
114	OCT Angiography Fractal Analysis of Choroidal Neovessels Secondary to Central Serous Chorioretinopathy, in a Caucasian Cohort. <i>Journal of Clinical Medicine</i> , 2022, 11, 1443.	1.0	6
115	Meteorin Is a Novel Therapeutic Target for Wet Age-Related Macular Degeneration. <i>Journal of Clinical Medicine</i> , 2021, 10, 2973.	1.0	5
116	Potential antiedematous effects of intravitreal anti-VEGF, unrelated to VEGF neutralization. <i>Drug Discovery Today</i> , 2019, 24, 1436-1439.	3.2	4
117	Type one macular neovascularization in central serous chorioretinopathy: Short-term response to anti-vascular endothelial growth factor therapy. <i>Eye</i> , 2022, 36, 1945-1950.	1.1	4
118	Irvine-Gass Macular Edema Responding to the Combination of Oral Mineralocorticoid-Receptor Antagonist With Dexamethasone Drops. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2017, 48, 936-942.	0.4	4
119	Clinical Characteristics and Multimodal Imaging Findings of Central Serous Chorioretinopathy in Women versus Men. <i>Journal of Clinical Medicine</i> , 2022, 11, 1706.	1.0	4
120	Effect of eplerenone on choroidal blood flow changes during isometric exercise in patients with chronic central serous chorioretinopathy. <i>Acta Ophthalmologica</i> , 2021, 99, e1375-e1381.	0.6	3
121	Evaluation of an Intravitreal Rho-Associated Kinase Inhibitor Depot Formulation in a Rat Model of Diabetic Retinopathy. <i>Pharmaceutics</i> , 2021, 13, 1105.	2.0	3
122	Retinal safety of intravitreal rtPA in healthy rats and under excitotoxic conditions. <i>Molecular Vision</i> , 2016, 22, 1332-1341.	1.1	3
123	Comparative Analysis of Urso- and Tauroursodeoxycholic Acid Neuroprotective Effects on Retinal Degeneration Models. <i>Pharmaceutics</i> , 2022, 15, 334.	1.7	3
124	Current and Future Treatments for Diabetic Retinopathy. <i>Pharmaceutics</i> , 2022, 14, 812.	2.0	3
125	Ocular Biodistribution of Spironolactone after a Single Intravitreal Injection of a Biodegradable Sustained-Release Polymer in Rats. <i>Molecular Pharmaceutics</i> , 2020, 17, 59-69.	2.3	2
126	Method for Retinal Gene Repair in Neonatal Mouse. <i>Methods in Molecular Biology</i> , 2014, 1114, 387-398.	0.4	1

#	ARTICLE	IF	CITATIONS
127	Letter to the Editor From Behar-Cohen et al.: â€œThe Cortisol Response of Male and Female Choroidal Endothelial Cells: Implications for Central Serous Chorioretinopathyâ€• Journal of Clinical Endocrinology and Metabolism, 2021, , .	1.8	1
128	Reply. Retina, 2014, 34, e20-e21.	1.0	0
129	Antidepressant medication and ocular factors in association with the need for anti-VEGF retreatment in neovascular age-related macular degeneration. British Journal of Ophthalmology, 2019, 103, 811-815.	2.1	0
130	Pathophysiology of CSCR. , 2019, , 3-10.		0
131	Central Serous Chorioretinopathy. Retina, 2021, Publish Ahead of Print, .	1.0	0
132	Mechanisms of Macular Edema. , 2017, , 7-25.		0